Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

• Main Authors: Rubin Cheng (Author), Yilan Huang (Author), Yun Fang (Author), Qirui Wang (Author), Meixiu Yan (Author), Yuqing Ge (Author)
• 格式: 圖書
• 出版: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• 主題: article
• 在線閱讀: Connect to this object online.

Context A portion of patients with chronic myeloid leukaemia (CML) develop resistance to the Bcr-Abl tyrosine kinase inhibitors (TKIs), limiting the clinical applications. Previous results have demonstrated the synergistic effects between cryptotanshinone (CPT) and imatinib on apoptosis of CML cells...